English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

ZAI Lab Announces Global Collaboration and License Agreement with UCB

Sep. 22, 2015

Zai Lab announced on September 22, 2015 that it has entered into a worldwide collaboration and license agreement with UCB, a global biopharmaceutical firm, to develop and commercialize a first-in-class monoclonal antibody for the potential treatment of autoimmune and other inflammatory diseases. The product is a clinical candidate ready for IND-enabling studies and expected to enter clinical Phase 1 in 2016.